OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
King of Prussia
James P. Catania is a managing consultant at Tunnell Consulting
A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
Executive management leadership is essential in the effective implementation of QbD.
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.